 | • レポートコード：MRC2312MG00258 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の放射性核種薬物複合体（RDC）市場規模と予測を収録しています。・世界の放射性核種薬物複合体（RDC）市場：売上、2018年-2023年、2024年-2029年 ・世界の放射性核種薬物複合体（RDC）市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の放射性核種薬物複合体（RDC）市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「抗体放射性核種複合体（ARC）」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 放射性核種薬物複合体（RDC）のグローバル主要企業は、POINT Biopharma、 Telix、 ITM AG、 Bayer AG、 Novartis、 Lantheus、 Curium Pharma、 Uihc Pet Imaging、 Grand Pharma、 BoomRay Pharmaceuticals、 SmartNuclide Biopharma、 Hengrui Medicine、 Yunnan Baiyao Group、 Sinotau、 Hexin Pharmaceutical、 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、放射性核種薬物複合体（RDC）のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の放射性核種薬物複合体（RDC）市場：タイプ別、2018年-2023年、2024年-2029年 世界の放射性核種薬物複合体（RDC）市場：タイプ別市場シェア、2022年 ・抗体放射性核種複合体（ARC）、ペプチド放射性核種複合体（PRC）、低分子放射性核種複合体（SMRC） 世界の放射性核種薬物複合体（RDC）市場：用途別、2018年-2023年、2024年-2029年 世界の放射性核種薬物複合体（RDC）市場：用途別市場シェア、2022年 ・神経内分泌腫瘍、前立腺癌、腎細胞癌 世界の放射性核種薬物複合体（RDC）市場：地域・国別、2018年-2023年、2024年-2029年 世界の放射性核種薬物複合体（RDC）市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における放射性核種薬物複合体（RDC）のグローバル売上、2018年-2023年 ・主要企業における放射性核種薬物複合体（RDC）のグローバル売上シェア、2022年 ・主要企業における放射性核種薬物複合体（RDC）のグローバル販売量、2018年-2023年 ・主要企業における放射性核種薬物複合体（RDC）のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 POINT Biopharma、 Telix、 ITM AG、 Bayer AG、 Novartis、 Lantheus、 Curium Pharma、 Uihc Pet Imaging、 Grand Pharma、 BoomRay Pharmaceuticals、 SmartNuclide Biopharma、 Hengrui Medicine、 Yunnan Baiyao Group、 Sinotau、 Hexin Pharmaceutical、 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. ************************************************************* ・調査・分析レポートの概要 放射性核種薬物複合体（RDC）市場の定義 市場セグメント 世界の放射性核種薬物複合体（RDC）市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の放射性核種薬物複合体（RDC）市場規模 世界の放射性核種薬物複合体（RDC）市場規模：2022年 VS 2029年 世界の放射性核種薬物複合体（RDC）市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの放射性核種薬物複合体（RDC）の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の放射性核種薬物複合体（RDC）製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：抗体放射性核種複合体（ARC）、ペプチド放射性核種複合体（PRC）、低分子放射性核種複合体（SMRC） 放射性核種薬物複合体（RDC）のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：神経内分泌腫瘍、前立腺癌、腎細胞癌 放射性核種薬物複合体（RDC）の用途別グローバル売上・予測 ・地域別市場分析 地域別放射性核種薬物複合体（RDC）市場規模 2022年と2029年 地域別放射性核種薬物複合体（RDC）売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） POINT Biopharma、 Telix、 ITM AG、 Bayer AG、 Novartis、 Lantheus、 Curium Pharma、 Uihc Pet Imaging、 Grand Pharma、 BoomRay Pharmaceuticals、 SmartNuclide Biopharma、 Hengrui Medicine、 Yunnan Baiyao Group、 Sinotau、 Hexin Pharmaceutical、 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. ... |
This research report provides a comprehensive analysis of the Radionuclide Drug Conjugates (RDC) market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Radionuclide Drug Conjugates (RDC) market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Radionuclide Drug Conjugates (RDC), challenges faced by the industry, and potential opportunities for market players.
The global Radionuclide Drug Conjugates (RDC) market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Radionuclide Drug Conjugates (RDC) market presents opportunities for various stakeholders, including Neuroendocrine Tumors, Prostate Cancer. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Radionuclide Drug Conjugates (RDC) market. Additionally, the growing consumer demand present avenues for market expansion.
The global Radionuclide Drug Conjugates (RDC) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.
According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.
At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.
According to different targeting ligands, RDC can be subdivided into: antibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).
According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.
Key Features:
The research report on the Radionuclide Drug Conjugates (RDC) market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Radionuclide Drug Conjugates (RDC) market.
Market Overview: The report provides a comprehensive overview of the Radionuclide Drug Conjugates (RDC) market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC)), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Radionuclide Drug Conjugates (RDC) market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Radionuclide Drug Conjugates (RDC) market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Radionuclide Drug Conjugates (RDC) market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Radionuclide Drug Conjugates (RDC) market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Radionuclide Drug Conjugates (RDC) market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Radionuclide Drug Conjugates (RDC) market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Radionuclide Drug Conjugates (RDC), including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Radionuclide Drug Conjugates (RDC) market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Radionuclide Drug Conjugates (RDC) market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)
Market segment by Application
Neuroendocrine Tumors
Prostate Cancer
Renal Cell Carcinoma
Global Radionuclide Drug Conjugates (RDC) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Uihc Pet Imaging
Grand Pharma
BoomRay Pharmaceuticals
SmartNuclide Biopharma
Hengrui Medicine
Yunnan Baiyao Group
Sinotau
Hexin Pharmaceutical
Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Radionuclide Drug Conjugates (RDC), market overview.
Chapter 2: Global Radionuclide Drug Conjugates (RDC) market size in revenue.
Chapter 3: Detailed analysis of Radionuclide Drug Conjugates (RDC) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Radionuclide Drug Conjugates (RDC) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Radionuclide Drug Conjugates (RDC) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Radionuclide Drug Conjugates (RDC) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Radionuclide Drug Conjugates (RDC) Overall Market Size
2.1 Global Radionuclide Drug Conjugates (RDC) Market Size: 2022 VS 2029
2.2 Global Radionuclide Drug Conjugates (RDC) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Radionuclide Drug Conjugates (RDC) Players in Global Market
3.2 Top Global Radionuclide Drug Conjugates (RDC) Companies Ranked by Revenue
3.3 Global Radionuclide Drug Conjugates (RDC) Revenue by Companies
3.4 Top 3 and Top 5 Radionuclide Drug Conjugates (RDC) Companies in Global Market, by Revenue in 2022
3.5 Global Companies Radionuclide Drug Conjugates (RDC) Product Type
3.6 Tier 1, Tier 2 and Tier 3 Radionuclide Drug Conjugates (RDC) Players in Global Market
3.6.1 List of Global Tier 1 Radionuclide Drug Conjugates (RDC) Companies
3.6.2 List of Global Tier 2 and Tier 3 Radionuclide Drug Conjugates (RDC) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Radionuclide Drug Conjugates (RDC) Market Size Markets, 2022 & 2029
4.1.2 Antibody Radionuclide Conjugates (ARC)
4.1.3 Peptide Radionuclide Conjugates (PRC)
4.1.4 Small Molecular Radionuclide Conjugates (SMRC)
4.2 By Type – Global Radionuclide Drug Conjugates (RDC) Revenue & Forecasts
4.2.1 By Type – Global Radionuclide Drug Conjugates (RDC) Revenue, 2018-2023
4.2.2 By Type – Global Radionuclide Drug Conjugates (RDC) Revenue, 2024-2029
4.2.3 By Type – Global Radionuclide Drug Conjugates (RDC) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Radionuclide Drug Conjugates (RDC) Market Size, 2022 & 2029
5.1.2 Neuroendocrine Tumors
5.1.3 Prostate Cancer
5.1.4 Renal Cell Carcinoma
5.2 By Application – Global Radionuclide Drug Conjugates (RDC) Revenue & Forecasts
5.2.1 By Application – Global Radionuclide Drug Conjugates (RDC) Revenue, 2018-2023
5.2.2 By Application – Global Radionuclide Drug Conjugates (RDC) Revenue, 2024-2029
5.2.3 By Application – Global Radionuclide Drug Conjugates (RDC) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Radionuclide Drug Conjugates (RDC) Market Size, 2022 & 2029
6.2 By Region – Global Radionuclide Drug Conjugates (RDC) Revenue & Forecasts
6.2.1 By Region – Global Radionuclide Drug Conjugates (RDC) Revenue, 2018-2023
6.2.2 By Region – Global Radionuclide Drug Conjugates (RDC) Revenue, 2024-2029
6.2.3 By Region – Global Radionuclide Drug Conjugates (RDC) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Radionuclide Drug Conjugates (RDC) Revenue, 2018-2029
6.3.2 US Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.3.3 Canada Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.3.4 Mexico Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Radionuclide Drug Conjugates (RDC) Revenue, 2018-2029
6.4.2 Germany Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.4.3 France Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.4.4 U.K. Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.4.5 Italy Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.4.6 Russia Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.4.7 Nordic Countries Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.4.8 Benelux Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Radionuclide Drug Conjugates (RDC) Revenue, 2018-2029
6.5.2 China Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.5.3 Japan Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.5.4 South Korea Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.5.5 Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.5.6 India Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Radionuclide Drug Conjugates (RDC) Revenue, 2018-2029
6.6.2 Brazil Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.6.3 Argentina Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Radionuclide Drug Conjugates (RDC) Revenue, 2018-2029
6.7.2 Turkey Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.7.3 Israel Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.7.4 Saudi Arabia Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
6.7.5 UAE Radionuclide Drug Conjugates (RDC) Market Size, 2018-2029
7 Radionuclide Drug Conjugates (RDC) Companies Profiles
7.1 POINT Biopharma
7.1.1 POINT Biopharma Company Summary
7.1.2 POINT Biopharma Business Overview
7.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.1.4 POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.1.5 POINT Biopharma Key News & Latest Developments
7.2 Telix
7.2.1 Telix Company Summary
7.2.2 Telix Business Overview
7.2.3 Telix Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.2.4 Telix Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.2.5 Telix Key News & Latest Developments
7.3 ITM AG
7.3.1 ITM AG Company Summary
7.3.2 ITM AG Business Overview
7.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.3.4 ITM AG Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.3.5 ITM AG Key News & Latest Developments
7.4 Bayer AG
7.4.1 Bayer AG Company Summary
7.4.2 Bayer AG Business Overview
7.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.4.4 Bayer AG Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.4.5 Bayer AG Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.5.4 Novartis Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Lantheus
7.6.1 Lantheus Company Summary
7.6.2 Lantheus Business Overview
7.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.6.4 Lantheus Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.6.5 Lantheus Key News & Latest Developments
7.7 Curium Pharma
7.7.1 Curium Pharma Company Summary
7.7.2 Curium Pharma Business Overview
7.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.7.4 Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.7.5 Curium Pharma Key News & Latest Developments
7.8 Uihc Pet Imaging
7.8.1 Uihc Pet Imaging Company Summary
7.8.2 Uihc Pet Imaging Business Overview
7.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.8.4 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.8.5 Uihc Pet Imaging Key News & Latest Developments
7.9 Grand Pharma
7.9.1 Grand Pharma Company Summary
7.9.2 Grand Pharma Business Overview
7.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.9.4 Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.9.5 Grand Pharma Key News & Latest Developments
7.10 BoomRay Pharmaceuticals
7.10.1 BoomRay Pharmaceuticals Company Summary
7.10.2 BoomRay Pharmaceuticals Business Overview
7.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.10.4 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.10.5 BoomRay Pharmaceuticals Key News & Latest Developments
7.11 SmartNuclide Biopharma
7.11.1 SmartNuclide Biopharma Company Summary
7.11.2 SmartNuclide Biopharma Business Overview
7.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.11.4 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.11.5 SmartNuclide Biopharma Key News & Latest Developments
7.12 Hengrui Medicine
7.12.1 Hengrui Medicine Company Summary
7.12.2 Hengrui Medicine Business Overview
7.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.12.4 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.12.5 Hengrui Medicine Key News & Latest Developments
7.13 Yunnan Baiyao Group
7.13.1 Yunnan Baiyao Group Company Summary
7.13.2 Yunnan Baiyao Group Business Overview
7.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.13.4 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.13.5 Yunnan Baiyao Group Key News & Latest Developments
7.14 Sinotau
7.14.1 Sinotau Company Summary
7.14.2 Sinotau Business Overview
7.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.14.4 Sinotau Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.14.5 Sinotau Key News & Latest Developments
7.15 Hexin Pharmaceutical
7.15.1 Hexin Pharmaceutical Company Summary
7.15.2 Hexin Pharmaceutical Business Overview
7.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.15.4 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.15.5 Hexin Pharmaceutical Key News & Latest Developments
7.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
7.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Summary
7.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
7.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Major Product Offerings
7.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue in Global Market (2018-2023)
7.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer